Upregulation of VEGF by 15-deoxy-Δ12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells

Annals of the New York Academy of Sciences

Volumn 1090, Issue , 2006, Pages 375-384

  Kim, Eun Hee ^a   Na, Hye Kyung ^a   Surh, Young Joon ^a  

^a Seoul National University   (South Korea)

Author keywords

15 deoxy 12,14 prostaglandin J2; ERK; Heme oxygenase 1; MCF 7 cells; VEGF

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; ACETYLCYSTEINE; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTOPORPHYRIN; VASCULOTROPIN; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; DRUG DERIVATIVE; HEME OXYGENASE; PRIMER DNA; PROSTAGLANDIN D2; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; WESTERN BLOTTING; ARTICLE; METABOLISM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HEME OXYGENASE (DECYCLIZING); HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247623569     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1378.041     Document Type: Conference Paper

References (32)

1. FOLKMAN, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1: 27-31.
2. FERRARA, N., H.P. GERBER & J. LECOUTER. 2003. The biology of VEGF and its receptors. Nat. Med. 9: 669-676.
3. CARMELIET, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3): 4-10.
4. LEE, J.C. et al. 2000. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer 36: 748-753.
5. POON, R.T., S.T. FAN & J. WONG. 2001. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19: 1207-1225.
6. SHIBUYA, M. 2001. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell. Struct. Funct. 26: 25-35.
7. NEUFELD, G. et al. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13: 9-22.
8. STRAUS, D.S. & C.K. GLASS. 2001. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21: 185-210.
9. BENNETT, A. 1986. The production of prostanoids in human cancers, and their implications for tumor progression. Prog. Lipid Res. 25: 539-542.
10. MARNETT, L.J. 1992. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52: 5575-5589.
11. 2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int. J. Oncol. 21: 915-920.
12. YAMAKAWA, K. et al. 2000. Peroxisome proliferator- activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 271: 571-574.
13. JOZKOWICZ, A. et al. 2003. Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid. Redox. Signal. 5: 155-162.
14. JOZKOWICZ, A. et al. 2000. Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim. Pol. 47: 1147-1157.
15. MAINES, M.D. 1988. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2: 2557-2568.
16. DULAK, J. et al. 2005. Heme oxygenase-1 and angiogenesis: therapeutic implications. In Heme Oxygenase. L.E. Otterbein & B.S. Zuckerbraun, Eds.: 245-270. Nova Science Publisher. New York.
17. CARMELIET, P. 2003. Angiogenesis in health and disease. Nat. Med. 9: 653-660.
18. SCHWENTKER, A., et al. 2002. Nitric oxide and wound repair: role of cytokines? Nitric Oxide 7: 1-10.
19. YANO, K., L.F. BROWN & M. DETMAR. 2001. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J. Clin. Invest. 107: 409-417.
20. GERBER, H.P., et al. 1999. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5: 623-628.
21. FERRARA, N. & R.S. KERBEL. 2005. Angiogenesis as a therapeutic target. Nature 438: 967-974.
22. DULAK, J. et al. 2004. Complex role of heme oxygenase-1 in angiogenesis. Antioxid. Redox. Signal. 6: 858-866.
23. MAINES, M.D. 1997. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37: 517-554.
24. OTTERBEIN, L.E. et al. 2003. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 24: 449-455.
25. SIKORSKI, E.M. et al. 2004. The story so far: molecular regulation of the heme oxygenase-1 gene in renal injury. Am. J. Physiol. Renal Physiol. 286: F425-F441.
26. KIMURA, H. et al. 2000. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95: 189-197.
27. FUKUDA, R. et al. 2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277: 38205-38211.
28. BERRA, E. et al. 2000. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 60: 1171-1178.
29. MILANINI-MONGIAT, J., J. POUYSSEGUR & G. PAGES. 2002. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277: 20631-20639.
30. RYTER, S.W., D. MORSE & A.M. CHOI. 2004. Carbon monoxide: to boldly go where NO has gone before. Sci. STKE. 230: RE6.
31. FORESTI, R. et al. 2004. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br. J. Pharmacol. 142: 453-460.
32. LI, M.H., Y.N. CHA & Y.-J. SURH. 2006. Carbon monoxide protects PC12 cells from peroxynitrite-induced apoptotic cell death by preventing the depolarization of mitochondrial transmembrane potential. Biochem. Biophys. Res. Commun. 342: 984-990.